Meta-analysis of the Association betweenRASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2015.07.09
- VernacularTitle:RASSF1A基因启动子甲基化与非小细胞肺癌关系的meta分析
- Author:
WEI HUIJUN
1
;
FANG NIANZHEN
;
GUO LILI
;
WU ZHIHAO
;
ZHOU QINGHUA
Author Information
1. 300052 天津，天津医科大学总医院，天津市肺癌研究所，天津市肺癌转移与肿瘤微环境重点实验室
- Keywords:
Lung neoplasms,ARSSF1A gene;
Methylation;
Meta-analysis
- From:
Chinese Journal of Lung Cancer
2015;(7):443-450
- CountryChina
- Language:Chinese
-
Abstract:
Background and objectivehTe CpG island aberrant promoter methylation in the tumor suppressor gene region plays an important role in the process of tumorigenesis. Relevant evidence shows that the promoter methylation of ARS association domain family 1A (ARSSF1A) gene, a tumor suppressor gene, has a close relationship with non-small cell lung cancer (NSCLC) development; therefore, ARSSF1A may be a potential NSCLC biomarker. hTis paper discussed and summa-rized the relationship betweenARSSF1A gene promoter methylation frequency and NSCLC throughmeta-analysis.Methods By searching Medline, EMBASE, CNKI, and Wanfang database, we selected and collected the published articles regarding RASSF1A gene promoter methylation and NSCLC risk according to the marked inclusion and exclusion criteria. Through meta-analysis, combined odds ratio (OR) and 95% confidence interval (CI) data were used to analyze theRASSF1A gene promoter methylation and NSCLC relationship.Results A total of 23 articles were utilized in this study. Results indicated that theARSSF1A gene promoter methylation rate was 41.50% (95%CI: 34%-49%) in NSCLC tissue and was 5.58% (95%CI: 2%-9%) for the control group. Compared with normal lung tissue, ARSSF1A methylation frequency in tumor tissue was sig-niifcantly higher than that of the control group (OR=8.72, 95%CI: 4.88-15.58,P<0.05). Subgroup analysis showed that the ARSSF1A gene promoter methylation rate of tumor tissue was higher than that of plasma group (OR=10.99, 95%CI: 2.48-48.68) and normal control tissue group (OR=8.74, 95%CI: 4.39-17.41).ConclusionhTe rate ofARSSF1A promoter gene methyla-tion in NSCLC patient tissue samples was higher than that of normal lung samples, whereas the rate ofARSSF1A promoter gene methylation in the tissue has more signiifcant effect on lung cancer occurrence. hTis ifnding indicates thatARSSF1A gene promoter methylation could be used as an NSCLC biomarker and was involved in NSCLC carcinogenic effects.
